Document is current
Any future updates will be listed below
-
Authors
Shiha, Gamal
Soliman, Reham
Elbasiony, Mohamed
Darwish, Noureldien H. E.
Mousa, Shaker A.
-
Funding
Funding for this research was provided by:
The Egyptian Liver Research Institute and Hospital (ELRIAH) clinical trial team and Virothera LLC supported the manufacturing and QC for Dactavira and Dactavira plus clinical batches.
- License Information
-
More Information
Article History
Received: 21 February 2019
Accepted: 30 August 2019
First Online: 19 September 2019
Competing Interests
: Gamal Shiha has been a Principal Investigator for Gilead and Abbvie. Reham Soliman has been an Investigator for Gilead and Abbvie. Mohamed Elbasiony has been an Investigator for Gilead. Shaker A Mousa has no conflict of interest other than helping HCV patients in underdeveloped countries have access to treatment at low to no cost. Noureldien H.E. Darwish declares no competing interests.
